The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may contribute to conditions like obesity and heart disease, a new study suggests.

Using social media as a pharma brand can feel risky due to regulatory constraints - but it can make a big impact when used in ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Studies show that people with psoriasis, especially those with severe cases, have a much higher risk of heart disease than ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

First, you’ve gotta know what you’re working with. While white folks usually get psoriasis ‘plaques’ that are pink or red, psoriasis shows up on Black folks as anything from darker brown to gray or ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Swiss biosimilars specialist Sandoz (SIX: SDZ) has launched what it says is the first autoinjector presentation of a biosimilar to Stelara (ustekinumab) in Europe, bolstering its presence in the ...

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...